Cognition Therapeutics (CGTX) Soars 12% After-Hours on Alzheimer's Trial Data

Cognition Therapeutics, Inc. (CGTX) experienced a significant drop of 9.55% today, but the share price rose to its highest level since February 2025, with an intraday gain of 8.47%.

Recent developments in Cognition Therapeutics, Inc. (CGTX) have significantly impacted its stock price. On July 9, 2025, the stock experienced high volatility, closing at $0.532 after a 9.55% drop from the previous day's close of $0.589. Despite this decline, the stock has shown a 77.43% increase over the past two weeks, indicating potential bullish sentiment. However, the stock is currently considered overbought on the RSI14 scale, suggesting a possible correction in the near term. Positive signals from both short and long-term moving averages provide a positive outlook, though recent negative signals may influence short-term performance. The stock is classified as high risk due to its volatility, with a recommended stop-loss at $0.503. Analysts have issued a hold recommendation, considering the stock's current status as favorable for accumulation. Furthermore, Cognition Therapeutics' shares have jumped 12% after hours following promising Phase 2 Alzheimer's trial data, highlighting clinical progress as a key driver of stock movement.